Migraine
Conditions
Keywords
Triptan, Drug utilization, Elderly, Drug abuse, Cardiovascular disease
Brief summary
This study will be conducted as a retrospective study of exposed and unexposed cohort of the French population included all beneficiaries aged 65 and older. Exposed patients will be matched to non exposed controls according age, gender and area of residence (ratio 1/4). Two exposed arms and two non exposed control arms will be planned. Triptan arm will be user of triptan defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users). Ergot arm will be user of ergot derivative defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users). This study involved data from the French National Health Insurance Information System (Système National dInformation Inter-Régimes de lAssurance Maladie ; SNIIRAM) linked with the French hospital discharge database (Programme de Médicalisation des Systèmes dInformations, PMSI). * The SNIIRAM is a vast national medico-administrative database representing the most part of the French population, allowing to identify and to describe precisely all medication dispensations (name of drug, date of dispensing and quantity) including triptans and other reimbursed medications. * The PMSI provides medical information about all patients admitted to hospital in France, including discharge diagnoses encoded according ICD-10, medical procedures and French diagnosis-related groups The research proposed is expected to provide an update and nationally-consolidated estimation of the cardiovascular risk is associated to triptans use in elderly population.
Interventions
DRUGExposure to Triptan
DRUGExposure to Ergot
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged 65 and more * Patients registered in the SNIIR-AM * To avoid depletion of susceptibles bias, only incident users will be included. Incident users are defined by the lack of reimbursement for triptan (or ergot derivatives) prior six months of the study period.
Exclusion criteria
no
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurence of the first vascular event leading to a hospitalization within the exposure period following the first dispensation of a triptan. | Up to 4 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the mortality: number of all deaths | Up to 4 years | Assessment of the deaths, whatever the cause |
| Assessment of the mortality with an underlying cardiovascular cause occuring in hospital | Up to 4 years | — |
Countries
France
Contacts
Primary ContactJoelle MICALLEF, MD-PhD
Backup ContactKahena AMICHI
Outcome results
None listed